Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020

Grössmann, N. (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020. Oncology Fact Sheet Nr. 6.

[thumbnail of Oncology Fact Sheet Nr.6_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
70kB

Item Type:	Oncology Fact Sheet
Subjects:	WB Practice of medicine > WB 300-962 Therapeutics QZ Pathology > QZ 200-380 Neoplasms.Cysts WH Hemic and lymphatic systems QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:	English
Series Name:	Oncology Fact Sheet Nr. 6
Deposited on:	15 Apr 2020 14:47
Last Modified:	31 Jul 2020 09:46

Repository Staff Only: item control page